Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial

NCT01706627 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

175

Enrollment

OTHER

Sponsor class

Conditions

Advanced Stage Cancer

Interventions

DRUG: 10 mg Melatonin
DRUG: 20 mg Melatonin
DRUG: Matched placebo

Sponsor

Khon Kaen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]